Korean Journal of Clinical Laboratory Science (대한임상검사과학회지)

Korean Society for Clinical Laboratory Science (대한임상검사과학회)
권호 표지
DOI QR코드

DOI QR Code

Study on Laboratory Diagnosis of the Ebola Virus and Its Current Trends

에볼라 바이러스 진단법과 개발 동향에 관한 고찰 연구

  • Jeong, Hye Seon (Department of Laboratory Medicine, St. Vincent Hospital, The Catholic University of Korea) ;
  • Kang, Yun-Jung (Department of Health Science, Dankook University Graduate School)
  • 정혜선 (가톨릭대학교 성빈센트병원 진단검사의학과) ;
  • 강윤정 (단국대학교 일반대학원 보건학과)
  • Received : 2015.07.17
  • Accepted : 2015.07.27
  • Published : 2015.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

In late December 2013, the Ebola virus emerged from West Africa. The outbreak started in Guinea and rapidly spread to Liberia and Sierra Leone. Initially, the virus is spread to the human population after contact with infected wildlife and then spread person-to-person through direct contact with body fluids such as blood, sweat, urine, semen, and breast milk. The Ebola virus infects endothelial cells, mononuclear phagocytes and hepatocytes. It causes massive damage to internal tissues and organs, such as blood vessels and the liver, and ultimately death. Most tests for the virus RNA rely on a technology called reverse-transcriptase polymerase chain reaction (RT-PCR). While this method is highly sensitive, it is also expensive, requiring skilled scientists, and delicate power supplies. The strip analytical technique (enzyme-linked immunosorbent assay or ELISA) detects antigens or antibodies to the Ebola virus. This test is cheap and does not require electricity or refrigeration. Despite ongoing efforts directed at experimental treatments and vaccine development, current medical work on the Ebola viral disease is largely limited to supportive therapy. Thus, rapid and reliable diagnoses of the Ebola virus are critically important for patient management, infections, prevention, and control measures.

2013년 12월 말, 에볼라 바이러스는 서아프리카에서 발발했다. 기니를 시작으로 라이베리아, 시에라리온으로 빠르게 퍼지게 되었다. 에볼라 바이러스(자이르형 에볼라 바이러스)는 외피, 비분절, 음성단일가닥 RNA바이러스이다. 에볼라 바이러스는 인수공통 전염병이다. 바이러스는 처음 감염된 야생동물과 접촉 한 후, 혈액, 땀, 소변, 정액, 모유 등의 체액과의 직접적인 접촉을 통해 사람 대 사람으로 전염된다. 그러나 공기로 전염되지는 않는다. 잠복기는 2~21일이다. 에볼라 바이러스는 내피세포, 단핵 식세포, 간세포를 감염시킨다. 감염 후 바이러스가 숙주의 면역 시스템을 회피하기 위해 여러 메커니즘을 사용한다. 이것은 혈관, 간 등의 내부 조직 및 기관에 막대한 피해를 주어 죽음에 이르게 한다. RNA 바이러스에 대한 대부분의 실험은 역전사 중합효소 연쇄반응(RT-PCR)라 기술에 의존한다. 이 방법은 매우 민감하지만 숙련된 과학자, 전원 공급 장치 요구하며 비싸다. 스트립 분석기법(효소면역분석법, ELISA)은 에볼라 바이러스 항원 또는 항체를 검출한다. 이 기법은 저렴하며, 전기, 냉장 장치가 필요하지 않다. 실험적인 치료 및 백신 개발에 관한 지속적인 노력에도 불구하고, 에볼라 바이러스 질환은 현재 치료법에 제한이 있다. 그러므로 신속하고 정확한 진단이 환자관리, 감염예방, 관리대책에 있어서 매우 중요하다.

Keywords

References

  1. Barrette RW, SA Metwally, JM Rowland, L Xu, SR Zaki, ST Nichol, P, et al. Discovery of swine as a host for the Reston ebolavirus. Science. 2009, 325(5937): 204-206. https://doi.org/10.1126/science.1172705
  2. Bausch DG, JS Towner, SF Dowell, F Kaducu, M. Lukwiya, A Sanchez, et al.. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. Journal of Infectious Diseases. 2007, 196(Supplement 2): S142-S147. https://doi.org/10.1086/520545
  3. Bwaka MA, M.J Bonnet, P Calain, R Colebunders, A De Roo, Y Guimard, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. Journal of Infectious Diseases. 1999, 179(Supplement 1): S1-S7. https://doi.org/10.1086/514308
  4. Dixon MG, IJ Schafer. Ebola viral disease outbreak-West Africa, 2014. MMWR Morb Mortal Wkly Rep 2014, 63(25):548-551.
  5. Feldmann H, TW Geisbert. Ebola haemorrhagic fever. The Lancet. 2001, 377(9768): 849-862.
  6. Feldmann H, HD Klenk. Marburg and Ebola viruses. Advances in Virus Research. 1996, 47: 1-52.
  7. Formenty P, C Hatz, B Le Guenno, A Stoll, P Rogenmoser, A Widmer. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. Journal of Infectious Diseases. 1999, 179(Supplement 1): S48-S53. https://doi.org/10.1086/514285
  8. Francesconi P, Z Yoti, S Declich, PA Onek, M Fabiani, J Olango, et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerging Infectious Diseases. 2003, 9(11):1430. https://doi.org/10.3201/eid0911.030339
  9. Geisbert TW, ACH Lee, M. Robbins, JB Geisbert, AN Honko, V Sood, et al.. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. The Lancet. 2010, 375(9729): 1896-1905. https://doi.org/10.1016/S0140-6736(10)60357-1
  10. Grolla A, A Lucht, D Dick, JE Stron, H Feldmann. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull Soc Pathol Exot. 2005, 98(3): 205.
  11. J Alimonti, A Leung, S Jones, J Gren, X Qiu, L Fernando, et al. Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory. Scientific Reports 4. 2014, doi:10.1038/srep05824.
  12. Jahrling PB, TW Geisbert, ED Johnson, CJ Peters, D Dalgard, W. Hall. Preliminary report: isolation of Ebola virus from monkeys imported to USA. The Lancet. 1990, 335(8688): 502-505. https://doi.org/10.1016/0140-6736(90)90737-P
  13. Kanapathipillai R, AM Henao Restrepo, P Fast, D Wood, C Dye, M.P Kieny, et al. Ebola vaccine-an urgent international priority. New England Journal of Medicine. 2014, 371(24): 2249-2251. https://doi.org/10.1056/NEJMp1412166
  14. Kilgore PE, JD Grabenstein, AM Salim, M. Rybak. Treatment of ebola virus disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015, 35(1): 43-53. https://doi.org/10.1002/phar.1545
  15. Kortepeter MG, DG Bausch, M Bray. "Basic clinical and laboratory features of filoviral hemorrhagic fever." Journal of Infectious Diseases. 2011, 204(suppl 3): S810-S816. https://doi.org/10.1093/infdis/jir299
  16. Leroy EM, S Baize, CY Lu, J McCormick, A Georges, M Georges-Courbot, et al. Diagnosis of Ebola haemorrhagic fever by RTPCR in an epidemic setting. Journal of Medical Virology. 2000, 60(4): 463-467. https://doi.org/10.1002/(SICI)1096-9071(200004)60:4<463::AID-JMV15>3.0.CO;2-M
  17. Martin P. KB Laupland, EH Frost, L. Valiquette. Laboratory diagnosis of Ebola virus disease. Intensive Care Medicine. 2015, 1-4.
  18. Oestereich L, A Ludtke, S Wurr, T Rieger, C Munoz-Fontela, S. Gunther. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research. 2014, 105: 17-21. https://doi.org/10.1016/j.antiviral.2014.02.014
  19. World Health Organization. Viral haemorrhagic fever in imported monkeys. Wkly Epidemiol Rec.1992, 67(142): 20849-26003.
  20. World Health Organization. Ebola virus disease. Fact sheet No. 103, updated September 2014.
  21. World Health Organization. Ebola situation report. WHO Geneva, MAY. 2015.
  22. Qiu X, G Wong, J Audet, A Bello, L Fernando, JB Alimonti, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014, doi:10.1038/nature13777.
  23. Saez AM, S Weiss, K Nowak, V Lapeyre, F Zimmermann, A Dux, et al.. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Molecular Medicine. 2015, 7(1): 17-23. https://doi.org/10.15252/emmm.201404792
  24. Schieffelin JS, JG Shaffer, A Goba, M Gbakie, SK Gire, A Colubri, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. New England Journal of Medicine. 2014, 371(22):2092-2100. https://doi.org/10.1056/NEJMoa1411680
  25. Smither SJ, LS Eastaugh, JA Steward, M Nelson, RP Lenk, M. S. Lever. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Research. 2014, 104: 153-155. https://doi.org/10.1016/j.antiviral.2014.01.012
  26. Towner JS, TK Sealy, ML Khristova, CG. Albarino, S Conlan, SA Reeder, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathogens. 2008, 4(11): e1000212. https://doi.org/10.1371/journal.ppat.1000212
  27. Volchkov VE, H Feldmann, VA Volchkova, HD Klenk. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proceedings of the National Academy of Sciences. 1998, 95(10): 5762-5767. https://doi.org/10.1073/pnas.95.10.5762
  28. Volchkov VE, VA Volchkova, E Muhlberger, LV Kolesnikova, M Weik, O Dolnik et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science. 2001, 291(5510): 1965-1969. https://doi.org/10.1126/science.1057269
  29. West TE, A von Saint Andre-von Arnim. Clinical Presentation and Management of Severe Ebola Virus Disease. Annals of the American Thoracic Society. 2014, 11(9): 1341-1350. https://doi.org/10.1513/AnnalsATS.201410-481PS
  30. Zaki SR, WJ Shieh, PW Greer, CS Goldsmith, T Ferebee, J Katshitshi, et al.. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Journal of Infectious Diseases. 1999, 179(Supplement 1): S36-S47. https://doi.org/10.1086/514319